City Therapeutics (NASDAQ:CTY) Stock Price Down 5% - Here's Why

Key Points

• City Therapeutics shares fell 5% to $18.63, after closing at $19.62; trading volume was 27% above its daily average. The article does not identify a specific cause for the decline.
• The company dosed the first participant in a Phase 1 trial of CITY-RBP4, its RNAi candidate for Stargardt disease and its second program to enter clinical development.
• New analyst coverage was mostly positive, with Buy or Outperform ratings and price targets of $32–$46; meanwhile, a director and a major shareholder each bought 170,000 shares at $18.00. Analysts noted that the company remains an early-stage biotech, so its programs carry development risk.

City Therapeutics, Inc. (NASDAQ:CTY - Get Free Report) traded down 5% on Wednesday. The stock traded as low as $18.09 and last traded at $18.63. Approximately 345,963 shares traded hands during trading, an increase of 27% from the average daily volume of 272,810 shares. The stock had previously closed at $19.62.

City Therapeutics News Summary

Investors following CTY have been watching these news items:

• Positive Sentiment: City dosed the first participant in a Phase 1 trial of CITY-RBP4, its RNAi candidate for Stargardt disease. The program targets RBP4 and is the company’s second to enter clinical development, adding a potential catalyst to its pipeline. Company announcement
• Positive Sentiment: New analyst coverage was broadly bullish: Oppenheimer rated CTY “outperform” with a $46 target, while Jefferies and Stifel initiated “buy” ratings with targets of $32 and $34, respectively. Those targets indicate analysts see substantial potential from the cited share price, though they depend on the company’s early-stage programs succeeding. Oppenheimer ratings Jefferies ratings Stifel ratings
• Neutral Sentiment: Goldman Sachs also began coverage, describing CTY as an “early-stage biotech.” That characterization underscores the development risk even as the company’s pipeline advances.

Wall Street Analysts Forecast Growth

CTY has been the subject of several research analyst reports. Stifel Nicolaus assumed coverage on City Therapeutics in a report on Tuesday. They issued a "buy" rating and a $34.00 price objective for the company. Jefferies Financial Group began coverage on City Therapeutics in a report on Tuesday. They issued a "buy" rating and a $32.00 target price on the stock. Wall Street Zen upgraded City Therapeutics to a "hold" rating in a research note on Saturday, October 24th. The Goldman Sachs Group began coverage on City Therapeutics in a research note on Tuesday. They set an "early-stage biotech" rating for the company. Finally, Oppenheimer began coverage on shares of City Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $46.00 price target for the company. Three analysts have rated the stock with a Buy rating. According to MarketBeat.com, City Therapeutics has a consensus rating of "Buy" and a consensus target price of $37.33.

City Therapeutics Stock Performance

Insider Buying and Selling at City Therapeutics

In related news, Director Robert Nelsen purchased 170,000 shares of City Therapeutics stock in a transaction on Monday, October 19th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $3,060,000.00. Following the completion of the transaction, the director directly owned 13,692,507 shares in the company, valued at $246,465,126. This represents a 1.26% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Arch Venture Partners Xii, Llc acquired 170,000 shares of the firm's stock in a transaction dated Monday, October 19th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the purchase, the insider directly owned 13,692,507 shares of the company's stock, valued at approximately $246,465,126. This trade represents a 1.26% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

About City Therapeutics

City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company's activities center on building a therapeutic pipeline rather than marketing established products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.